Skip to main content

Advertisement

SpringerLink
Log in

Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer

  • Original Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to analyze the clinicopathological features and treatment outcomes of ovarian metastasis from gastric cancer.

Methods

This study included 155 female patients with unresectable advanced or recurrent gastric cancer at the Kochi Medical School between January 2007 and December 2021. A review of patients with ovarian metastasis was conducted, and their clinicopathological information and survival outcomes were compared with respect to ovarian metastasis.

Results

Fifteen patients were diagnosed with ovarian metastasis from gastric cancer with a median age of 54 years (range: 30–87 years) and an incidence of 9.7%. The median age of patients who developed ovarian metastasis was significantly lower those without ovarian metastasis (54 years vs. 71 years, P = 0.014). The median survival time (MST) for 15 patients with unresectable advanced gastric cancer who developed ovarian metastasis was 21.4 months (range: 0.2–41.4 months). The MST for 15 patients who underwent surgical resection and systemic drug treatment including chemotherapy to ovarian metastasis was significantly higher than those who received systemic drug treatment alone (28.1 months vs. 10.0 months; P = 0.021).

Conclusion

Ovarian metastasis was found in 9.7% of female patients with unresectable advanced or recurrent gastric cancer and in younger patients than in those without ovarian metastasis. Multidisciplinary treatment, including surgical resection and systemic drug treatment for ovarian metastasis from gastric cancer, may benefit selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, Ono H, Tanabe S, Kaminishi M (2013) Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16:1–27

    Article  Google Scholar 

  2. Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F (2017) Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol 18:1579–1589

    Article  Google Scholar 

  3. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112

  4. Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Tamura T, Yatabe T, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K (2019) Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer. Gastric Cancer 22:684–691

    Article  CAS  Google Scholar 

  5. Aurello P, Berardi G, Antolino L, Antonelli G, Rampini A, Moschetta G, Ramacciato G (2018) Is a surgical approach justified in metachronous Krukenberg tumor from gastric cancer? A systematic review. Oncol Res Treat 41:644–649

    Article  Google Scholar 

  6. Krukenberg FE (1896) Uber Das Fibrosarcoma ovarii mucocellulare (carcinomatodes). Arch Gynak 50:287–321

    Article  Google Scholar 

  7. Qiu L, Yang T, Shan XH, Hu MB, Li Y (2011) Metastatic factors for Krukenberg tumor: a clinical study on 102 cases. Med Oncol 28:1514–1519

    Article  Google Scholar 

  8. Cho JH, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, Cho JY (2015) Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with Krukenberg tumor. Cancer Res Treat 47:697–705

    Article  CAS  Google Scholar 

  9. Japanese Gastric Cancer Association (2021) Japanese gastric cancer treatment guidelines 2018 5th edition. Gastric Cancer 24:1–21.

  10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, Investigators TT (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  CAS  Google Scholar 

  11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221

    Article  CAS  Google Scholar 

  12. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069.

  13. Wang J, Shi YK, Wu LY, Wang JW, Yang S, Yang JL, Zhang HZ, Liu SM (2008) Prognostic factors for ovarian metastases from primary gastric cancer. Int J Gynecol Cancer 18:825–832

    Article  CAS  Google Scholar 

  14. Kubeček O, Laco J, Špaček J, Petera J, Kopecký J, Kubečková A, Filip S (2017) The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis 34:295–307

    Article  Google Scholar 

  15. Kakushima N, Kamoshida T, Hirai S, Hotta S, Hirayama T, Yamada J, Ueda K, Sato M, Okumura M, Shimokama T, Oka Y (2003) Early gastric cancer with Krukenberg tumor and review of cases of intramucosal gastric cancers with Krukenberg tumor. J Gastroenterol 38:1176–1180

    Article  Google Scholar 

  16. Fujimoto D, Hirono Y, Goi T, Yamaguchi A (2016) Sigmoid colonic metastasis by lymphatic spread occurring with unilateral Krukenberg tumor considered to be caused by stage IA early gastric cancer: a case report. Oncol Lett 11:668–672

    Article  Google Scholar 

  17. Jeung YJ, Ok HJ, Kim WG, Kim SH, Lee TH (2015) Krukenberg tumors of gastric origin versus colorectal origin. Obstet Gynecol Sci 58:32–39

    Article  Google Scholar 

  18. Seow-En I, Hwarng G, Tan GHC, Ho LML, Teo MCC (2018) Palliative surgery for Krukenberg tumors −12-year experience and review of the literature. World J Clin Oncol 9:13–19

    Article  Google Scholar 

  19. Wu XJ, Yuan P, Li ZY, Bu ZD, Zhang LH, Wu AW, Zong XL, Li SX, Shan F, Ji X, Ren H, Ji JF (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol 34:463–469

    Article  CAS  Google Scholar 

  20. Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M, Cozzaglio L, Pedrazzani C, Berardi S, Baiocchi GL, Roviello F, Portolani N, de Manzoni G, Costamagna G, Doglietto GB, Pacelli F (2016) Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 40:921–928

    Article  Google Scholar 

  21. Yan D, Du Y, Dai G, Huang L, Xu Q, Yu P (2018) Management of synchronous Krukenberg tumors from gastric cancer: a single-center experience. J Cancer 9:4197–4203

    Article  CAS  Google Scholar 

  22. F, Li Y, Li W, Kang W, Liu H, Ma S, Xie Y, Zhong Y, Xu Q, Wang B, Xue L, Tian Y, (2019) Metastasectomy improves the survival of gastric cancer patients with Krukenberg tumors: a retrospective analysis of 182 patients. Cancer Manag Res 11:10573–10580

    Article  Google Scholar 

  23. Sandhu S, Arafat O, Patel H, Lall C (2012) Krukenberg tumor: a rare cause of ovarian torsion. J Clin Imaging Sci 2:6

    Article  Google Scholar 

  24. Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL, Cheng AL, Yeh KH (2012) Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 32:3397–3401

    PubMed  Google Scholar 

  25. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH (2004) Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol 87:39–45

    Article  Google Scholar 

  26. Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, Guo WJ (2013) Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS ONE 8:e68227

    Article  CAS  Google Scholar 

  27. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS (2012) Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 21:20–38

    Article  CAS  Google Scholar 

  28. Ur Rahman MS, Cao J (2016) Estrogen receptors in gastric cancer: advances and perspectives. World J Gastroenterol 22:2475–2482

    Article  Google Scholar 

  29. Li SQ, Zhang KC, Li JY, Liang WQ, Gao YH, Qiao Z, Xi HQ, Chen L (2020) Establishment and validation of a nomogram to predict the risk of ovarian metastasis in gastric cancer: based on a large cohort. World J Clin Cases 8:4331–4341

    Article  Google Scholar 

  30. Wang B, Tang Q, Xu L, Teng X, Ding W, Ren G, Wang X (2021) A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors. Mod Pathol 34:42–50

    Article  CAS  Google Scholar 

  31. Wang B, Sun K, Zou Y (2017) Comparison of a panel of biomarkers between gastric primary cancer and the paired Krukenberg tumor. Appl Immunohistochem Mol Morphol 25:639–644

    Article  CAS  Google Scholar 

  32. Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476–484

    Article  Google Scholar 

  33. Boku N (2014) HER2-positive gastric cancer. Gastric Cancer 17:1–12

    Article  CAS  Google Scholar 

  34. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A and RAINBOW Study Group (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235

    Article  Google Scholar 

  35. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471

    Article  CAS  Google Scholar 

  36. Namikawa T, Marui A, Yokota K, Fujieda Y, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K (2021) Successful conversion surgery for advanced gastric cancer with multiple liver metastases following ramucirumab plus paclitaxel combination treatment. In Vivo 35:2929–2935

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the contributions of our colleagues from the Department of Surgery, Kochi Medical School.

Author information

Authors and Affiliations

  1. Department of Surgery, Kochi Medical School, Kohasu,Oko-cho, Nankoku, 783-8505, Japan

    Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yasuhiro Kawanishi, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa & Kazuhiro Hanazaki

  2. Department of Human Health and Medical Sciences, Kochi Medical School, Kochi, Japan

    Michiya Kobayashi

Authors
  1. Tsutomu Namikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Marui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiichiro Yokota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhiro Kawanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaya Munekage
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sunao Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiromichi Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michiya Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuhiro Hanazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception and design: Tsutomu Namikawa.

Acquisition of data: Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yasuhiro Kawanishi, Masaya Munekage, Sunao Uemura, Hiroyuki Kitagawa, Michiya Kobayashi.

Analysis and interpretation of data: Tsutomu Namikawa and Hiromichi Maeda.

Drafting of manuscript: Tsutomu Namikawa.

Critical revision of manuscript: Tsutomu Namikawa and Kazuhiro Hanazaki.

Corresponding author

Correspondence to Tsutomu Namikawa.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Namikawa, T., Marui, A., Yokota, K. et al. Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer. Langenbecks Arch Surg 407, 2301–2308 (2022). https://doi.org/10.1007/s00423-022-02543-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-022-02543-3

Keywords

Search

Navigation